A Phase II Study of Nivolumab and Ipilimumab with Radiation Therapy in Patients with Metastatic, Microsatellite Stable Colorectal Cancer.
The combination of immune-modulating, non-ablative doses of radiation therapy with ipilimumab and nivolumab has selective clinical activity in refractory MSS CRC, with responses concentrated primarily in patients without active liver metastases.